ArcherDX

Read more
Jason Myers's photo - President & CEO of ArcherDX

President & CEO

Jason Myers

CEO Approval Rating

98/100

Founded:

2013

Status:

PrivateSubsidiary of Invitae Corp.

Est. Annual Revenue
$50.5M
Agree?
Est. Employees
260
Agree?

ARCHERDX TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

ArcherDX's company profile
Jason Myers's photo - President & CEO of ArcherDX

Jason Myers

President & CEO

98/100
260
$175.1M
$50.5M
View Profile
1
ArcherDX's Competitor - Adaptive Biotechnologies logo
Chad Robins's photo - Chairman & CEO of Adaptive Biotechnologies

Chad Robins

Chairman & CEO

80/100
622
$720.8M
$115.9M
View Profile
2
ArcherDX's Competitor - Asuragen logo
Matthew McManus's photo - President & CEO of Asuragen

Matthew McManus

President & CEO

85/100
200
$82M
$30M
View Profile
3
ArcherDX's Competitor - Swift Biosciences logo
Nathan Wood's photo - President & CEO of Swift Biosciences

Nathan Wood

President & CEO

89/100
60
$34.8M
$11.2M
View Profile
4
ArcherDX's Competitor - BioVision logo
Gordon Yan's photo - Co-Founder & CEO of BioVision

Gordon Yan

Co-Founder & CEO

87/100
109
- -
$33.8M
View Profile
5
ArcherDX's Competitor - Cayman Chemical logo
Kirk M. Maxey's photo - President & CEO of Cayman Chemical

Kirk M. Maxey

President & CEO

89/100
400
$8.2M
$47M
View Profile
6
ArcherDX's Competitor - BPS Bioscience logo
Henry Zhu's photo - President & CEO of BPS Bioscience

Henry Zhu

President & CEO

69/100
80
- -
$9M
View Profile
7
ArcherDX's Competitor - Critical Diagnostics logo
Dennis Dalangin's photo - CEO of Critical Diagnostics

Dennis Dalangin

CEO

82/100
29
$11.1M
$7.8M
View Profile
8
ArcherDX's Competitor - Labome logo
CEO Avatar

CEO

- -
- -
View Profile
9
ArcherDX's Competitor - Promega logo
William A. Linton's photo - Chairman & CEO of Promega

William A. Linton

Chairman & CEO

79/100
1,730
- -
$450M
View Profile
10
ArcherDX's Competitor - Aetna logo
CEO Avatar

CEO

- -
47,950
- -
$69.6B
View Profile
11
ArcherDX's Competitor - PGDx logo
Megan Bailey's photo - CEO of PGDx

Megan Bailey

CEO

84/100
200
$323.2M
$16M
View Profile

Missing a competitor? Contribute!

Adaptive Biotechnologies is perceived as one of ArcherDX's biggest rivals. Adaptive Biotechnologies was founded in 2009, and its headquarters is in Seattle, Washington. Adaptive Biotechnologies competes in the Biotechnology field. Adaptive Biotechnologies has 362 more employees than ArcherDX.

Asuragen is one of ArcherDX's top rivals. Asuragen is a Private company that was founded in 2006 in Austin, Texas. Asuragen operates in the Health Care Services industry. Compared to ArcherDX, Asuragen has 60 fewer employees.

Swift Biosciences is ArcherDX's #3 rival. Swift Biosciences is a Private company that was founded in Ann Arbor, Michigan in 2013. Swift Biosciences is in the Biotechnology industry. Swift Biosciences has 200 fewer employees vs. ArcherDX.

ArcherDX Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Baby Genes, Inc.

Jan 2019

Source »
undisclosed
Baby Genes is a provider of newborn screening and confirmatory testing kits.

These are all the companies that ArcherDX has acquired. ArcherDX's latest acquisition was Baby Genes, Inc. in Jan 2019. Baby Genes is a provider of newborn screening and confirmatory testing kits.

ArcherDX Funding History

Since ArcherDX was founded in 2013, it has participated in 7 rounds of funding. In total ArcherDX has raised $175.1M. ArcherDX's last funding round was on Apr 2020 for a total of $1.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Unattributed
Apr 2020
$1.6M
Unattributed
Feb 2020
$1.3M
Unattributed
Dec 2019
$4.6M
-
Series C
Dec 2019
$55M
Series B
May 2019
$60M

Since ArcherDX was founded in 2013, it has participated in 7 rounds of funding. In total ArcherDX has raised $175.1M. ArcherDX's last funding round was on Apr 2020 for a total of $1.6M

ArcherDX Investments

No recent investments found related to ArcherDX

ArcherDX News

August 7, 2020Micro Small Cap

Natera Files Additional Suit Against ArcherDX

SAN CARLOS, Calif., Aug. 7, 2020 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a pioneer and global lea... See more »
August 2, 2020InnovationNews

ArcherDX and UCL extend TRACERx program collaboration to evaluate cancer evolution

BOULDER and LONDON -- ArcherDX, Inc., UCL and the Francis Crick Institute today announced an extensio... See more »
June 26, 2020BizWest

ArcherDX abandons IPO for $1.4B acquisition

Welcome to Funding Friday, BizWest's weekly roundup of companies in Northern Colorado and the Boulder... See more »
June 23, 2020The Business Journals: Denver

Boulder biotech company to be acquired for $1.4B

Just a few weeks ago, the company filed for an IPO. Now, it's being acquired.... See more »
June 23, 2020BizWest

Scale the deciding factor in choosing $1.4B acquisition over going public

BOULDER - ArcherDX Inc. CEO Jason Myers said his company would have had a "white-hot" initial public ... See more »
June 23, 2020FierceBiotech

ArcherDX drops IPO plans in favor of a $1.4B takeover by Invitae

ArcherDX drops IPO plans in favor of a $1.4B takeover by Invitae chale Tue, 06/23/2020 - 10:18... See more »
June 22, 2020Investor’s Business Daily

Genetic Testing Behemoth Invitae Rockets 38% On $1.4 Billion Acquisition

Invitae announced a $1.4 billion plan Monday to acquire genetic testing company ArcherDX in a deal th... See more »

ArcherDX Blogs

August 5, 2020ArcherDX Blog

ArcherDX to Participate in UBS Genomics 2.0 and Medtech Innovations Virtual Summit

ArcherDX to Participate in UBS Genomics 2.0 and Medtech Innovations Virtual Summit  BOULDER, Col... See more »
May 7, 2020ArcherDX Blog

ArcherDX Appoints Jason Ryan to Board of Directors

BOULDER, Colo., May 7, 2020 /PRNewswire/ — ArcherDX, Inc. today announced the appointment of Ja... See more »
April 28, 2020ArcherDX Blog

ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting

First presentation of the data utilizing ArcherDX’s proprietary Anchored Multiplex PCR (AMP™) technol... See more »
April 16, 2020ArcherDX Blog

Letter from Chief Executive Officer and Co-founder, Jason Myers

Over the course of the last several weeks, our lives have been disrupted in ways we would not have pr... See more »
January 14, 2020ArcherDX Blog

ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device

First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate a... See more »
January 10, 2020ArcherDX Blog

ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests

Co-marketing partnership to drive awareness of ArcherDX IVD products and increase access to vital gen... See more »
January 8, 2020ArcherDX Blog

ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Jan. 8, 2020 /PRNewswire/ - ArcherDX, Inc., a molecular diagnostics company dedicated... See more »

ArcherDX Press Releases

November 7, 2017PR Newswire

ArcherDX, Celgene ink Worldwide Companion Diagnostic Agreement relating to Investigational Drug CC-122

BOULDER, Colo., Nov. 7, 2017 /PRNewswire/ -- ArcherDX announced today that it has signed an agreement... See more »
June 1, 2017Marketwired

MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries

PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - June 01, 2017) - MolecularMD Corp., a molecular diagno... See more »
November 3, 2015BUSINESS WIRE

ArcherDX and GenomOncology to Collaborate on NGS Workflow Applications

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX, Inc. has announced an agreement with GenomOncology, Inc. t... See more »
October 13, 2015PR NEWSWIRE

ArcherDX Launches NGS Solution for Comprehensive Lung and Thyroid Tumor Profiling

BOULDER, Colo., Oct. 13, 2015 /PRNewswire/ -- ArcherDX, Inc., announced an addition to its target enr... See more »
September 28, 2015BUSINESS WIRE

ArcherDX and BioChain to Provide NGS-characterized FFPE Tumor Samples

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX will characterize tumor FFPE samples supplied by BioChain t... See more »
September 1, 2015BUSINESS WIRE

ArcherDX Launches VariantPlex p53 Panel for Targeted NGS

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX launches the Archer VariantPlex p53 Panel, a targeted NGS-b... See more »
August 18, 2015BUSINESS WIRE

ArcherDX Launches PreSeq for FFPE Input QC

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX today launched PreSeq QC Assays to assess the quality of DN... See more »

ArcherDX Videos

Social Media

ArcherDX Headquarters

2477 55th Street Suite 202

Boulder, Colorado80301

1-877-771-1093

Driving Directions »

Trending Companies

ArcherDX Summary

ABOUT

Overview

ArcherDX is a bioinformatics company that develops and commercializes NGS-based gene fusion detection assays for oncology applications. ArcherDX was founded in 2013. ArcherDX's headquarters is located in Boulder, Colorado, USA 80301. It has raised 175...

CEO

ArcherDX's President & CEO, Jason Myers, currently has an approval rating of 98%. ArcherDX's primary competitors are Adaptive Biotechnologies, Asuragen & Swift Biosciences.

Frequently Asked Questions about ArcherDX

  1. When was ArcherDX founded?

    ArcherDX was founded in 2013
  2. Who is ArcherDX's CEO?

    ArcherDX's CEO is Jason Myers
  3. How much revenue does ArcherDX generate?

    ArcherDX generates $50.5M in revenue
  4. How much funding does ArcherDX have?

    ArcherDX has historically raised $175.1M in funding
  1. Where is ArcherDX's headquarters?

    ArcherDX's headquarters is in Boulder Colorado, USA
  2. How many employees does ArcherDX have?

    ArcherDX has 260 employees
  3. What sector does ArcherDX operate in?

    ArcherDX is in Health Care Supplies
  4. Who are ArcherDX's competitors?

    ArcherDX's top competitors are Adaptive Biotechnologies, Asuragen, Swift Biosciences